• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    8/11/22 4:31:13 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (AMENDMENT NO. 16)

     

    ProPhase Labs, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0005 per share

    (Title of Class of Securities)

     

    74345W 10 8

    (CUSIP Number)

     

    Herbert Kozlov, Esq.

    Wendy Grasso, Esq.

    Reed Smith LLP

    599 Lexington Avenue

    New York, New York 10022

    (212) 521-5400

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 10, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

     

     
     

     

    CUSIP No: 74345W 10 8

     

    1. NAME OF REPORTING PERSON:  
      Ted Karkus  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
      (See Instructions):  
      (a) ☐  
      (b) ☐  
         
    3. SEC USE ONLY  
         
    4. SOURCE OF FUNDS (See Instructions) PF
         
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e): ☐
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION United States

     

    NUMBER OF 7. SOLE VOTING POWER 4,488,609 (1)
    SHARES      
    BENEFICIALLY 8. SHARED VOTING POWER 100,000 (2)
    OWNED BY      
    EACH 9. SOLE DISPOSITIVE POWER 4,488,609 (1)
    REPORTING      
    PERSON WITH 10. SHARED DISPOSITIVE POWER 100,000 (2)

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      4,588,609 shares of common stock (1)  
         
    12.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    (See Instructions)

    ☐
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 25.9% (2)
         
    14. TYPE OF REPORTING PERSON (See Instructions) IN

     

     

     

    (1) Includes 1,700,000 shares of common stock issuable to the Reporting Person upon the exercise of stock options, which are currently vested and exercisable.

     

    (2) These 100,000 shares are held by the Reporting Person’s son, who resides with him, for which he may be deemed the beneficial owner.

     

    (2) Based on 16,006,222 shares of common stock outstanding on August 10, 2022, plus 1,700,000 shares of Common Stock issuable to the Reporting Person upon the exercise of stock options, which are currently vested and exercisable.

     

     
     

     

    Introductory Note:

     

    This Amendment No. 16 amends and supplements the Statement on Schedule 13D filed by Ted Karkus (the “Reporting Person”) on April 27, 2011 (the “Original Schedule 13D”, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed on November 15, 2011, Amendment No. 2 to the Schedule 13D filed on December 14, 2011, Amendment No. 3 to the Schedule 13D filed on May 18, 2012, Amendment No. 4 to the Schedule 13D filed on September 19, 2014, Amendment No. 5 to the Schedule 13D filed on May 27, 2015, Amendment No. 6 to the Schedule 13D filed on June 8, 2015, Amendment No. 7 to the Schedule 13D filed on January 6, 2017, Amendment No. 8 to the Schedule 13D filed on May 3, 2017, Amendment No. 9 to the Schedule 13D filed on October 3, 2017, Amendment No. 10 to the Schedule 13D filed on December 26, 2017, Amendment No. 11 to the Schedule 13D filed on February 26, 2018, Amendment No. 12 to the Schedule 13D filed on March 30, 2020, Amendment No. 13 to the Schedule 13D filed on August 17, 2020, Amendment No. 14 to the Schedule 13D filed on May 10, 2021 , Amendment No. 15 to the Schedule 13D filed on May 26, 2022, and together with this Amendment No. 16, the “Schedule 13D”) to the extent specifically set forth below. Except as otherwise indicated, capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Schedule 13D.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended by inserting the following:

     

    On August 10, 2022, the Reporting Person acquired net 283,395 shares of common stock upon the exercise of stock options to purchase 600,000 shares of common stock, less 316,605 shares of common stock withheld to cover the exercise price and applicable taxes.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    As of the date hereof, the Reporting Person is deemed to be the beneficial owner, within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, of 4,588,609 shares of common stock of the Issuer (including 1,700,000 shares of common stock issuable to the Reporting Person upon the exercise of stock options, which are currently vested and exercisable), as well as 100,000 shares held by one of the Reporting Person’s sons, who resides with him, for approximately 25.9% of the Issuer’s shares outstanding. The Reporting Person has sole voting and dispositive power with respect to 4,588,609 shares and shared voting and dispositive power with respect to the 100,000 shares held by his son who resides with him, for which he may be deemed the beneficial owner. The Reporting Person disclaims beneficial ownership of the shares held by his other son who does not reside with him.

     

    Except for the exercise of stock options described above in this Item 5, there have been no other transactions in the securities of the Issuer effected by the Reporting Person in the last 60 days.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 11, 2022

     

     

    /s/ Ted Karkus

      Ted Karkus

     

     

    Get the next $PRPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE

    COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiative to the key next step. This bankruptcy action is strictly limited to the Company's COVID-19 lab testing units, which are collectively owed tens of millions of dollars by insurance companies. Successful collections have th

    9/23/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Continues its Exploration of a Crypto Treasury Strategy

    UNIONDALE, NY, Sept. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics and consumer products company, announced that the Company entered into an agreement relating to potential advisory services. Management continues to evaluate a range of options for potential allocation of balance sheet resources, including the possibility of investing in digital assets. "Following our stockholders' approval of all proxy items at the September 9 Special Meeting, ProPhase is now positioned to advance its crypto treasury strategy," said Ted Karkus, CEO and Chairman of ProPhase Labs. "We believe that we have significant underly

    9/22/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor

    ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company's September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear authorization to move forward with its strategic initiatives, including a significant increase in authorized shares to 1 billion. This success follows the re-election of the Board at the June annual meeting by in exce

    9/12/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    SEC Filings

    View All

    ProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    9/18/25 4:05:46 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    9/15/25 9:16:13 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    8/28/25 6:15:42 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO & CHAIRMAN Karkus Ted William

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    9/11/25 4:05:22 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:15:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hollenshead Stuart

    3 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:00:11 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    1/14/22 6:36:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

    12/20/21 6:25:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase downgraded by Dawson James

    Dawson James downgraded ProPhase from Buy to Neutral

    10/13/21 10:48:44 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

    GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

    2/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Unveils Project ZenQ-AI

    Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

    4/16/24 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Financials

    Live finance-specific insights

    View All

    ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

    ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s

    8/13/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

    UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a re

    8/11/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

    Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

    5/20/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    3/19/24 4:18:00 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/5/23 4:37:55 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/4/23 4:25:33 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care